Lyons Wealth Management LLC. reduced its position in Amgen, Inc. (NASDAQ:AMGN) by 17.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 3,926 shares of the medical research company’s stock after selling 848 shares during the period. Amgen accounts for about 1.6% of Lyons Wealth Management LLC.’s holdings, making the stock its 25th biggest holding. Lyons Wealth Management LLC.’s holdings in Amgen were worth $813,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of the company. FMR LLC increased its position in Amgen by 4.4% in the 3rd quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock valued at $7,425,805,000 after acquiring an additional 1,505,266 shares during the period. CI Global Investments Inc. increased its position in Amgen by 10.4% in the 3rd quarter. CI Global Investments Inc. now owns 2,869 shares of the medical research company’s stock valued at $595,000 after acquiring an additional 270 shares during the period. Rafferty Asset Management LLC increased its position in Amgen by 6.9% in the 3rd quarter. Rafferty Asset Management LLC now owns 10,703 shares of the medical research company’s stock valued at $2,219,000 after acquiring an additional 691 shares during the period. Blue Fin Capital Inc. increased its position in Amgen by 10.0% in the 3rd quarter. Blue Fin Capital Inc. now owns 7,449 shares of the medical research company’s stock valued at $1,544,000 after acquiring an additional 677 shares during the period. Finally, Skba Capital Management LLC increased its position in Amgen by 36.9% in the 3rd quarter. Skba Capital Management LLC now owns 77,500 shares of the medical research company’s stock valued at $16,065,000 after acquiring an additional 20,900 shares during the period. 77.91% of the stock is owned by institutional investors and hedge funds.
Several equities analysts recently issued reports on AMGN shares. Cann restated a “buy” rating and issued a $224.00 price target on shares of Amgen in a research report on Monday, October 1st. Royal Bank of Canada restated a “neutral” rating and issued a $193.00 price target on shares of Amgen in a research report on Monday, September 10th. Oppenheimer restated a “buy” rating and issued a $224.00 price target on shares of Amgen in a research report on Tuesday, August 28th. Goldman Sachs Group reiterated a “buy” rating and set a $229.00 target price on shares of Amgen in a research report on Friday, October 12th. Finally, Jefferies Financial Group set a $220.00 target price on Amgen and gave the stock a “buy” rating in a research report on Monday, October 8th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $204.55.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. The company had revenue of $5.90 billion for the quarter, compared to analysts’ expectations of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.27 EPS. As a group, equities research analysts forecast that Amgen, Inc. will post 14.24 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Investors of record on Friday, November 16th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio is currently 41.97%.
COPYRIGHT VIOLATION NOTICE: “Lyons Wealth Management LLC. Trims Stake in Amgen, Inc. (AMGN)” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/12/01/lyons-wealth-management-llc-trims-stake-in-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: How to Invest in an Index Fund
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.